Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367837407> ?p ?o ?g. }
- W4367837407 endingPage "285" @default.
- W4367837407 startingPage "275" @default.
- W4367837407 abstract "PURPOSE Intravitreal injection of bevacizumab (IVB) offers advantages over laser photoablation for treatment of type 1 retinopathy of prematurity (ROP). However, retinal function has not, to date, been quantitatively compared following these interventions. Therefore, electroretinography (ERG) was used compare retinal function among eyes treated using IVB or laser, and control eyes. In addition, among the IVB-treated eyes, ERG was used to compare function in individuals in whom subsequent laser was and was not required. DESIGN Prospective clinical cohort study. METHODS ERG was used to record dark- and light-adapted stimulus/response functions in 21 children treated using IVB (12 of whom required subsequent laser in at least 1 eye for persistent avascular retina [PAR]). Sensitivity and amplitude parameters were derived from the a-wave, b-wave, and oscillatory potentials (OPs), representing activity in photoreceptor, postreceptor, and inner retinal cells, respectively. These parameters were then referenced to those of 76 healthy, term-born controls and compared to those of 10 children treated using laser only. RESULTS In children with treated ROP, every ERG parameter was significantly below the mean in controls. However, these significant ERG deficits did not differ between IVB- and laser-treated eyes. Among children treated using IVB, no ERG parameter was significantly associated with dose or need for subsequent laser. CONCLUSION Retinal function was significantly impaired in treated ROP eyes. Function in IVB-treated eyes did not differ from that in laser-treated eyes. Functional differences also did not distinguish those IVB-treated eyes that would subsequently need laser for PAR. Intravitreal injection of bevacizumab (IVB) offers advantages over laser photoablation for treatment of type 1 retinopathy of prematurity (ROP). However, retinal function has not, to date, been quantitatively compared following these interventions. Therefore, electroretinography (ERG) was used compare retinal function among eyes treated using IVB or laser, and control eyes. In addition, among the IVB-treated eyes, ERG was used to compare function in individuals in whom subsequent laser was and was not required. Prospective clinical cohort study. ERG was used to record dark- and light-adapted stimulus/response functions in 21 children treated using IVB (12 of whom required subsequent laser in at least 1 eye for persistent avascular retina [PAR]). Sensitivity and amplitude parameters were derived from the a-wave, b-wave, and oscillatory potentials (OPs), representing activity in photoreceptor, postreceptor, and inner retinal cells, respectively. These parameters were then referenced to those of 76 healthy, term-born controls and compared to those of 10 children treated using laser only. In children with treated ROP, every ERG parameter was significantly below the mean in controls. However, these significant ERG deficits did not differ between IVB- and laser-treated eyes. Among children treated using IVB, no ERG parameter was significantly associated with dose or need for subsequent laser. Retinal function was significantly impaired in treated ROP eyes. Function in IVB-treated eyes did not differ from that in laser-treated eyes. Functional differences also did not distinguish those IVB-treated eyes that would subsequently need laser for PAR." @default.
- W4367837407 created "2023-05-04" @default.
- W4367837407 creator A5008165270 @default.
- W4367837407 creator A5015052483 @default.
- W4367837407 creator A5027457879 @default.
- W4367837407 creator A5051881574 @default.
- W4367837407 creator A5051938235 @default.
- W4367837407 creator A5058640057 @default.
- W4367837407 creator A5060385245 @default.
- W4367837407 creator A5067429045 @default.
- W4367837407 creator A5084149772 @default.
- W4367837407 date "2023-08-01" @default.
- W4367837407 modified "2023-10-17" @default.
- W4367837407 title "Electroretinographic Responses in Retinopathy of Prematurity Treated Using Intravitreal Bevacizumab or Laser" @default.
- W4367837407 cites W1222739530 @default.
- W4367837407 cites W128426766 @default.
- W4367837407 cites W1482826935 @default.
- W4367837407 cites W1490224842 @default.
- W4367837407 cites W1497517793 @default.
- W4367837407 cites W1502902760 @default.
- W4367837407 cites W1581832620 @default.
- W4367837407 cites W1603758502 @default.
- W4367837407 cites W1708589260 @default.
- W4367837407 cites W1923883771 @default.
- W4367837407 cites W1964934266 @default.
- W4367837407 cites W1965792818 @default.
- W4367837407 cites W1970624897 @default.
- W4367837407 cites W1991092593 @default.
- W4367837407 cites W1991994600 @default.
- W4367837407 cites W1995854663 @default.
- W4367837407 cites W2003982930 @default.
- W4367837407 cites W2003999217 @default.
- W4367837407 cites W2014386715 @default.
- W4367837407 cites W2016846438 @default.
- W4367837407 cites W2017605349 @default.
- W4367837407 cites W2020632226 @default.
- W4367837407 cites W2020919921 @default.
- W4367837407 cites W2024664315 @default.
- W4367837407 cites W2039936409 @default.
- W4367837407 cites W2042282733 @default.
- W4367837407 cites W2051605681 @default.
- W4367837407 cites W2055570088 @default.
- W4367837407 cites W205588752 @default.
- W4367837407 cites W2056898486 @default.
- W4367837407 cites W2060049117 @default.
- W4367837407 cites W2061738739 @default.
- W4367837407 cites W2062265875 @default.
- W4367837407 cites W2067626374 @default.
- W4367837407 cites W2069903330 @default.
- W4367837407 cites W2071599504 @default.
- W4367837407 cites W2073002561 @default.
- W4367837407 cites W2073324143 @default.
- W4367837407 cites W2077211907 @default.
- W4367837407 cites W2078044428 @default.
- W4367837407 cites W2083538148 @default.
- W4367837407 cites W2084726394 @default.
- W4367837407 cites W2087344433 @default.
- W4367837407 cites W2092158709 @default.
- W4367837407 cites W2101535867 @default.
- W4367837407 cites W2105191005 @default.
- W4367837407 cites W2109127976 @default.
- W4367837407 cites W2112068141 @default.
- W4367837407 cites W2113170046 @default.
- W4367837407 cites W2134950472 @default.
- W4367837407 cites W2162629754 @default.
- W4367837407 cites W2169013731 @default.
- W4367837407 cites W2255944078 @default.
- W4367837407 cites W2310164779 @default.
- W4367837407 cites W2318076598 @default.
- W4367837407 cites W2320813801 @default.
- W4367837407 cites W2429701438 @default.
- W4367837407 cites W2522889752 @default.
- W4367837407 cites W2782724554 @default.
- W4367837407 cites W2980057845 @default.
- W4367837407 cites W2993148976 @default.
- W4367837407 cites W3155555497 @default.
- W4367837407 cites W4220821050 @default.
- W4367837407 cites W4229018298 @default.
- W4367837407 cites W4248231685 @default.
- W4367837407 cites W71001787 @default.
- W4367837407 cites W2731335936 @default.
- W4367837407 doi "https://doi.org/10.1016/j.ajo.2023.04.014" @default.
- W4367837407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37146743" @default.
- W4367837407 hasPublicationYear "2023" @default.
- W4367837407 type Work @default.
- W4367837407 citedByCount "0" @default.
- W4367837407 crossrefType "journal-article" @default.
- W4367837407 hasAuthorship W4367837407A5008165270 @default.
- W4367837407 hasAuthorship W4367837407A5015052483 @default.
- W4367837407 hasAuthorship W4367837407A5027457879 @default.
- W4367837407 hasAuthorship W4367837407A5051881574 @default.
- W4367837407 hasAuthorship W4367837407A5051938235 @default.
- W4367837407 hasAuthorship W4367837407A5058640057 @default.
- W4367837407 hasAuthorship W4367837407A5060385245 @default.
- W4367837407 hasAuthorship W4367837407A5067429045 @default.
- W4367837407 hasAuthorship W4367837407A5084149772 @default.
- W4367837407 hasConcept C103796816 @default.
- W4367837407 hasConcept C118487528 @default.